Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) provided a corporate update on its barium and iodine contrast media projects, outlining a strategic roadmap to address supply chain vulnerabilities in the diagnostic imaging sector. The global contrast media market is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's strategy focuses on creating a secure, vertically integrated supply chain for both barium and iodine active pharmaceutical ingredients (APIs). This encompasses the entire value chain from mineral discovery to finished product manufacturing.
The company is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek (FC) barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate. Recent testing confirmed an average grade of 98.8% BaSO4, exceeding the pharmaceutical grade threshold of 97.5%. Voyageur has completed product development for five Health Canada approved barium products with Alberta Veterinary Laboratories and generated approximately C$32,000 in initial contrast product sales, establishing commercial validation.
FDA regulatory pathways for barium and iodine contrast media are expected to follow an 18 to 24-month review and approval process, potentially enabling U.S. barium market entry as soon as mid-2027 to late 2027. Voyageur has completed first drafts of all barium FDA submission documents and formally commenced the approval process in February 2026 via the 505(b)(2) regulatory pathway. The review process is anticipated to take approximately one year, with product testing projected at six to seven months.
For iodine contrast media, Voyageur is independently advancing a prefeasibility study integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project targets 35 million doses per year of iodine contrast drug production using iodine-rich brine from U.S. oil and gas operations. Additionally, the Bayer Iodine Project focuses on completing a BFS with potential second-phase offtake-linked production financing from Bayer, where Bayer would provide capital financing while Voyageur operates and manages the project. All intellectual property developed will remain exclusively owned by Voyageur.
The company is engaging a global engineering company to complete the final two BFS for the radiology drug manufacturing project and the Bayer Iodine project. Upon completion, Voyageur will have finalized the economics and plant design to vertically produce iodine and barium contrast media drugs from Earth to Bottle, becoming the only vertically integrated radiology drug company in the marketplace. The company is targeting construction to commence in 2027, subject to funding based on finalized feasibility studies.
Voyageur is building a strong network of clients in Canada and developing international sales through clinics and distribution opportunities in Latin America, Middle East, North Africa, and Asia-Pacific regions. These efforts provide market intelligence on pricing and cost dynamics amid supply shortages, while identifying favorable conditions for distribution agreements and regulatory registrations.
This disclosure has been reviewed and approved by Bradley Willis, P.Eng, a non-independent Qualified Person as defined by National Instrument 43-101. For further information, visit https://voyageurpharmaceuticals.ca.
